| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| VitB1/Thiamine Vitamin B1 (thiamine) is an essential water-soluble vitamin required for carbohydrate metabolism and mitochondrial energy production. Its active form, thiamine pyrophosphate (TPP), is a cofactor for key enzymes including pyruvate dehydrogenase (PDH), α-ketoglutarate dehydrogenase (α-KGDH), and transketolase. In Alzheimer’s disease (AD), thiamine deficiency and reduced activity of thiamine-dependent enzymes have been repeatedly observed in brain tissue. Impaired glucose metabolism is a hallmark of AD (“type 3 diabetes” hypothesis), and thiamine-dependent enzyme dysfunction contributes to mitochondrial impairment, oxidative stress, and neuronal vulnerability. Experimental studies suggest thiamine and lipophilic derivatives (e.g., benfotiamine) may improve glucose metabolism, reduce advanced glycation end products (AGEs), attenuate oxidative stress, and modulate neuroinflammation. Clinical data are mixed but suggest possible benefit in selected populations or with higher-bioavailability derivatives. Benfotiamine is a fat-soluble derivative of vitamin B1 (thiamine) that’s used to support nerve health, glucose metabolism, and potentially brain function, including in conditions like Alzheimer’s disease (AD) and diabetic neuropathy. -fat-soluble form, so may absorb better when taken with a meal containing fat. Condition / Purpose Typical Dose Range Notes Alzheimer’s Disease (AD) 300–600 mg/day Used in clinical trials (e.g., 300 mg twice daily) Diabetic Neuropathy 300–600 mg/day Most common clinical application General Cognitive Support 150–300 mg/day Lower end for maintenance High-dose experimental use 900–1,200 mg/day Occasionally used under supervision in research Alzheimer’s Disease Table: Vitamin B1 (Thiamine)
TSF: P = minimal immediate effect; R = metabolic enzyme activation; G = long-term neuroprotective adaptation. Thiamine vs Benfotiamine Comparison Table
|
| Source: |
| Type: |
| Destruction of mitochondrial transmembrane potential, which is widely regarded as one of the earliest events in the process of cell apoptosis. Mitochondria are organelles within eukaryotic cells that produce adenosine triphosphate (ATP), the main energy molecule used by the cell. For this reason, the mitochondrion is sometimes referred to as “the powerhouse of the cell”. Mitochondria produce ATP through process of cellular respiration—specifically, aerobic respiration, which requires oxygen. The citric acid cycle, or Krebs cycle, takes place in the mitochondria. The mitochondrial membrane potential is widely used in assessing mitochondrial function as it relates to the mitochondrial capacity of ATP generation by oxidative phosphorylation. The mitochondrial membrane potential is a reliable indicator of mitochondrial health. In cancer cells, ΔΨm is often decreased, which can lead to changes in cellular metabolism, increased glycolysis, increased reactive oxygen species (ROS) production, and altered cell death pathways. The membrane of malignant mitochondria is hyperpolarized (−220 mV) in comparison to their healthy counterparts (−160 mV), which facilitates the penetration of positively charged molecules to the cancer cells mitochondria. The MMP is a critical indicator of mitochondrial function, directly reflecting the organelle's capacity to generate ATP through oxidative phosphorylation. |
| 1888- | VitB1/Thiamine, | DCA, | High Dose Vitamin B1 Reduces Proliferation in Cancer Cell Lines Analogous to Dichloroacetate |
| - | in-vitro, | PC, | SK-N-BE | - | NA, | PC, | PANC1 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:264 Target#:197 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid